Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “BIOVERATIV THERAPEUTICS INC.”

57 pharma patents match "BIOVERATIV THERAPEUTICS INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 57
Index total 30,257
Page 2 / 3

Quick answer

This filtered view shows 57 pharmaceutical patents matching "BIOVERATIV THERAPEUTICS INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

57 results for “BIOVERATIV THERAPEUTICS INC.” · 30,257 patents in full index Clear search

  1. US 10968442

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  2. US 10927362

    Processable single chain molecules and polypeptides made using same

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted
  3. US 10898554

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted
  4. US 10881742

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  5. US 10786554

    Factor VIII polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  6. US 10772942

    Lyophilized factor IX formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  7. US 10745680

    Factor IX fusion proteins and methods of making and using same

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  8. US 10588949

    Factor IX polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  9. US 10584147

    Procoagulant fusion compound

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  10. US 10568943

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  11. US 10561714

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  12. US 10548953

    Factor VIII-XTEN fusions and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  13. US 10548954

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  14. US 10421798

    Factor VIII compositions and methods of making and using same

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  15. US 10391152

    Methods of using a fixed dose of a clotting factor

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  16. US 10370430

    Recombinant factor VIII proteins

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  17. US 10325687

    Population pharmacokinetics tools and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 18, 2019 · Expires Jun 13, 2039

    granted
  18. US 10287564

    Procoagulant compounds

    BIOVERATIV THERAPEUTICS INC. · Granted May 14, 2019 · Expires May 9, 2039

    granted
  19. US 10221455

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted
  20. US 10202595

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  21. US 10138291

    Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  22. US 10023628

    Cell line expressing single chain factor VIII polypeptides and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  23. US 10010622

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted
  24. US 10001495

    Blood factor monitoring assay and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted